WuXi Biologics (Cayman) Inc.

WXXWY | OTC

Price Alert Chart Builder DCF Calculator

$12.12

-$0.36 (-2.88%)

At close: Nov 5, 2026, 3:58 PM ET

$12.16

+$0.04 (+0.33%)

After-hours: Nov 5, 2026, 1:15 PM ET

Overview Rating Statistics Financials Earnings Ownership Profile

-2.88%

(1D)

No price chart data available for 1D timeframe.

Rating

Updated: Nov 5, 2026

65.1

Fundamentals Strong

Market Sentiment Neutral

Moat Narrow

Sector Rank #89/1024 (Top 9%)

Full Analysis

Key Statistics

Market Data

Market Cap $24.71B

1D Range

12.02 12.60

52W Range

7.45 14.79

Valuation (TTM)

PE 73.95

PB 3.59

EV/EBITDA 18.37

Valuation (NTM)

Forward PE 23.37

Forward PEG 1.05

Price Target $0.00

Cash Flow

FCF Yield 1.6%

SBC Adj. FCF Yield 1.4%

SBC Impact -16.3%

Margins

Gross Margin 47.5%

Operating Margin 32.4%

FCF Margin 11.8%

Growth (CAGR)

Revenue 3Y | 5Y 76.2% | 102.8%

Dil EPS 3Y | 5Y 54.5% | 101.5%

FCF 3Y | 5Y 404.6% | 162.6%

Returns

ROA 7.7%

ROE 10.5%

ROIC 10.6%

Financial Health

Net Cash

¥12.36B ($1.82B)

Current Ratio 3.04

Interest Coverage 74.60

Dividends

Div Yield N/A

Payout Ratio N/A

FCF Payout Ratio N/A

All Key Statistics

Loading financial charts...

Profile

WuXi Biologics (Cayman) Inc. delivers integrated solutions covering the entire lifecycle of biological drug development, from initial discovery to full-scale manufacturing. These services are provided...

Sector Healthcare

Industry Biotechnology

Employees 13,252

IPO Date Dec 18, 2017

Website www.wuxibiologics.com

Fiscal Year n/a

Full Company Profile

Latest News

2 months ago · seekingalpha.com

WuXi Biologics (Cayman) Inc. (WXXWY) Q2 2026 Earnings Call Transcript

4 months ago · prnewswire.com

WuXi Biologics' 25th Drug Substance Facility Completes First GMP Production, Manufacturing Process Execution with Zero Deviations

SHANGHAI, June 24, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that its MFG17 drug substance facility located at the Shanghai Fengxian site has successfully completed its first GMP production campaign. The manufacturing process execution was completed with zero deviations, while critical process parameters remained stable and yields reached expected levels, demonstrating robust process performance and strong execution capabilities.

5 months ago · prnewswire.com

WuXi Biologics' Suzhou Biosafety Testing Center Received Fourth EMA GMP Certification, Enabling 19 Commercial Products for the European Market

SUZHOU, China, June 18, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that its Biosafety Testing Center in Suzhou has successfully passed a Good Manufacturing Practice (GMP) inspection by the European Medicines Agency (EMA) with zero critical findings. This marks the fourth time the facility has successfully received EMA GMP certificate.

Earnings

Next Earnings

Mar 23, 2027

EPS Est

Pro

Rev Est

Pro

Earnings Details ➞